In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Five-year clinical outcomes in patients with moderate coronary artery spasm as assessed by intracoronary acetylcholine provocation test

Session Poster session 2

Speaker Yong Hoon Kim

Event : ESC Congress 2016

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session

Authors : Y H Kim (Chuncheon,KR), S-W Rha (Seoul,KP), A-Y Her (Chuncheon,KR), B-G Choi (Seoul,KP), SH Park (Seoul,KP), CU Choi (Seoul,KP), CG Park (Seoul,KP), HS Seo (Seoul,KP), DJ Oh (Seoul,KP), SY Choi (Seoul,KP), JK Byun (Seoul,KP), H Li (Seoul,KP), S-H Park (Cheonan-si,KR), JY Park (Daejeon,KR), JH Ahn (Gumi,KR)

Authors:
Y.H. Kim1 , S.-W. Rha2 , A.-Y. Her1 , B.-G. Choi2 , S.H. Park2 , C.U. Choi2 , C.G. Park2 , H.S. Seo2 , D.J. Oh2 , S.Y. Choi2 , J.K. Byun2 , H. Li2 , S.-H. Park3 , J.Y. Park4 , J.H. Ahn5 , 1Kangwon National University School of Medicine - Chuncheon - Korea Republic of , 2Korea University Guro Hospital - Seoul - Korea Republic of , 3Soonchunhyang University Hospital - Cheonan - Korea Republic of , 4Eulji University - Seoul - Korea Republic of , 5Soon Chun Hyang University Gumi Hospital - Gumi - Korea Republic of ,

Citation:
European Heart Journal ( 2016 ) 37 ( Abstract Supplement ), 387-388

Background: Previous studies showed that long-term clinical outcomes of patients (pts) with severe (subtotal or total occlusion) coronary artery spasm (CAS) during acetylcholine (Ach) provocation test were poor. However, there is no available convincing data regarding long-term clinical outcomes of pts with moderate CAS (borderline 50–70% transient narrowing) by Ach provocation test. We compared the 5-year clinical outcomes in pts with moderate CAS compared to severe CAS.

Method: A total 912 consecutive pts without significant coronary artery disease who underwent Ach provocation test between Nov. 2004 and Dec. 2015 were enrolled. Moderate CAS or severe CAS was defined as 50–70% or >70% of narrowing by quantitative coronary angiography with incremental intracoronary injection of 20, 50 and 100ug of Ach infusion. To adjust potential confounders, a propensity score- matched (PSM) analysis was performed using logistic regression model.

Results: After PSM analysis, 2 propensity-matched groups (356 pairs, n=712, C-statistic = 0.653) were generated. The 5-year cumulative incidences of cardiac death (0.8% vs 1.1%), percutaneous coronary intervention (1% vs 1%), myocardial infarction (1.1% vs 0.8%) and cerebrovascular accidents (1.1% vs 0.8%) were not significantly different between 2 groups (Table).

Conclusion: In our study, individual and composite major clinical outcomes were similar between the moderate CAS pts and severe CAS pts up to 5 years.

Clinical outcomes upto 5 years
Variables N (%) Propensity score-matched patients
TotalModerate (n=356)Severe (n=356)p-value
Outcomes at 5-year follow-up
 Cardiac death7 (1.0)3 (0.8)4 (1.1)0.809
 Percutaneous coronary intervention14 (2.0)7 (1.0)7 (1.0)NS
 Myocardial infarction7 (1.0)4 (1.1)3 (0.8)0.809
 Cerebrovascular accidents7 (1.0)4 (1.1)3 (0.8)0.809
Cumulative clinical outcomes up to 5 years.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are